This Month in JNM

April 4, 2016

 

Interventional molecular imaging: Solomon and Cornelis provide an introductory focus on interventional opportunities for molecular imaging, including guidance to localize targets, tissue analysis to confirm localization, in-room posttherapy assessment, and monitoring of targeted therapeutics. Page 493

18F-FMISO hypoxia imaging: Muzi and Krohn offer perspective on noninvasive assessment of hypoxia with 18F-fluromisonidazole PET and comment on a related article in this issue of JNM. Page 497

New PET, old remedies: Civelek previews an article in this issue of JNM that uses molecular imaging to elucidate mechanisms underlying a combined approach of stem cell therapy and traditional Chinese medicine in stroke. Page 499

RGD PET in oncology: Niu and Chen look at advances in integrin-targeted imaging probes based on the Arg-Gly-Asp tripeptide sequence and discuss an article in this issue of JNM using RGD-based PET in oncologic screening and therapy response monitoring. Page 501

Individualized 90Y-labeled DOTATATE therapy: Kletting and colleagues develop and validate a treatment planning modeling method to determine the optimal combination of peptide amount and associated activity for each patient undergoing peptide receptor radionuclide therapy. Page 503

PET prognosis in hepatocellular carcinoma: Lee and colleagues assess the predictive value of 18F-FDG uptake in patients with hepatocellular carcinoma after transarterial chemoembolization or concurrent intraarterial chemotherapy with external-beam radiotherapy. Page 509

Radioembolization for liver metastases: Fendler and colleagues evaluate the safety, efficacy, and prognostic factors for 90Y-labeled microsphere radioembolization of unresectable liver metastases from breast cancer. Page 517

RGD PET and GBM CRT: Zhang and colleagues examine the value of a novel 1-step labeled integrin αvβ3-targeting 18F-AlF-NOTA-PRGD2 PET scan in assessing sensitivity to concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma multiforme. Page 524

Perfusion and 18F-FAZA uptake: Iqbal and colleagues use 15O-H2O PET data to explore the relationship between tumor perfusion and 18F-fluoroazomycin arabinoside uptake in PET imaging of tumor hypoxia in patients with non–small cell lung cancer. Page 530

Prognostic PET/CT in TNBC: Groheux and colleagues describe the utility of 18F-FDG PET/CT at baseline and after 2 cycles of chemotherapy in predicting pathologic complete response and outcomes in patients with triple-negative breast cancer. Page 536

Tracer avidity and gastric cancer recurrence: Kim and colleagues ask whether the performance of PET in detecting gastric cancer recurrence is enhanced in patients with advanced 18F-FDG–avid primary tumors. Page 544

SPECT/MR fusion for SLNs: Hoogendam and colleagues explore the accuracy of 99mTc-nanocolloid SPECT/MR image fusion for selective assessment of nonenlarged sentinel lymph nodes in diagnosing metastases in early-stage cervical cancer patients. Page 551

68Ga-RM2 and 68Ga-PSMA in prostate cancer: Minamimoto and colleagues present pilot data on the biodistribution of these PET tracers in patients with biochemically recurrent prostate cancer and describe the potential for personalized imaging biomarker assessments. Page 557

68Ga-PSMA PET and intraprostatic cancer: Rahbar and colleagues evaluate the diagnostic value and accuracy of prostate-specific membrane antigen–targeting PET for intraprostatic delineation of prostate cancer before prostatectomy. Page 563

Improving cardiac suppression for PET: Scholtens and colleagues compare the effectiveness of 3 preparatory protocols in suppression of cardiac glucose metabolism in 18F-FDG PET studies performed to detect cardiac inflammation and infection. Page 568

Kinetic analysis of (S)-18F-THK5117: Jonasson and colleagues report on tracer kinetic models for quantitative analysis and generation of parametric images for this novel tau ligand in patients with Alzheimer disease and mild cognitive impairment. Page 574

PET/MR vs. PET/CT in lung lesions: Sawicki and colleagues compare 18F-FDG PET/MR imaging performance with that of 18F-FDG PET/CT in detecting and characterizing lung lesions in oncologic patients. Page 582

Attenuation correction in PET/MR imaging: An and colleagues introduce an improved ultrashort echo time MR image–based attenuation correction method and compare it with manufacturer-provided CT- and MR-based methods in healthy volunteers and individuals with Parkinson disease. Page 587

Intraperitoneal RIT dosimetry: Palm and colleagues describe a biokinetic model for evaluation and optimization of intraperitoneal radioimmunotherapies for micrometastatic tumors and use derived data to calculate optimal therapeutic approaches. Page 594

Liposomal uptake and EPR effect: Bolkestein and colleagues use injected 111In-labeled pegylated liposomes and serial SPECT/CT imaging to evaluate the influence of the enhanced permeability and retention effect on liposomal distribution. Page 601

Optimizing tau imaging agents: Tago and colleagues synthesize and evaluate a range of new 2-arylquinoline derivatives as potential PET tracers for identification of hyperphosphorylated tau protein in neurodegenerative disease. Page 608

Renal 11C-metformin PET/CT: Jakobsen and colleagues explore in a rat model the potential of 11C-labeled metformin as a PET tracer for quantification of kidney proximal tubule function and estimation of renal function. Page 615

PET and bacterial infection: Vilche and colleagues synthesize and evaluate the biologic characteristics of the cationic peptide 68Ga-NOTA-UBI-29-41 for PET/CT differentiation of infection from sterile inflammation. Page 622

11C-methyl-taurine–conjugated bile acids: Schacht and colleagues report on radiosynthesis of N-11C-methyl-taurine–conjugated bile acids and PET/CT biodistribution studies in pigs and discuss the potential for translation to functional imaging in patients with cholestatic diseases. Page 628

18F-fluoroproline for protein labeling: Harada and colleagues describe the development of a cell-free translation system and an 18F-labeled macromolecule for synthesis and characterization of 18F-interleukin-8. Page 634

Molecular imaging of VLA-4: Soodgupta and colleagues detail ex vivo and in vivo PET evaluation of overexpressed very-late-antigen-4, a transmembrane adhesion receptor that plays an important role in cancer and immune responses, in multiple myeloma. Page 640

Evaluation of mobile PET/CT: Grogg and colleagues analyze and report on the performance of a novel mobile human brain/small-animal PET/CT system designed as a low-cost device with the capability of battery-powered propulsion, enabling use in many settings. Page 646

Efficacy of targeted imaging agents: Graham and Weber present an adaptation of Fryback and Thornbury’s hierarchical scheme for modeling the efficacy of diagnostic imaging systems, specifically directed toward evaluating targeted imaging agents and streamlining the radiopharmaceutical approval process. Page 653